Abdallah Othman

08/08/2025

NuSH therapies reduce CV events in obesity with ASCVD/HFpEF, improving risk factors, physical function, and exercise capacity via weight-independent mechanisms.

07/08/2025

Electrocardiographic Findings in Cardiomyopathies:

07/08/2025

🔴SGLT2 Inhibitors: Cardio-Metabolic & Multiorgan Benefits
Cardiovascular:
Heart Failure: Cuts risk (HFrEF/HFpEF) with preload/afterload modulation, hemodynamic effects, and anti-inflammatory action.
BP Reduction: Natriuresis-driven volume depletion enhances hypertension control.
Metabolic Shift: Promotes ketogenesis & energy deficit, boosting myocardial efficiency.
Renal Protection:
Preserves eGFR, reduces albuminuria via tubuloglomerular feedback and antifibrotic effects.
Metabolic/Liver:
Improves lipid profiles (↓LDL/triglycerides, ↑HDL) via ANGPTL4 inhibition.
Reduces hepatic steatosis/fibrosis and transaminases (ALT/AST/GGT).
Emerging Effects:
Neuroprotection: May lower dementia risk by mitigating neuroinflammation/oxidative stress.
Gut: Modulates NF-κB/IL-6 to reduce inflammation.
Antitumor: Alters tumor metabolism (Warburg effect reversal) and enhances PD-L1 degradation.
Caveat: Potential bone resorption (↑PTH/FGF-23, ↓calcium absorption).

07/08/2025

🔴SGLT2 Inhibitors: Cardio-Metabolic & Multiorgan Benefits
Cardiovascular:
Heart Failure: Cuts risk (HFrEF/HFpEF) with preload/afterload modulation, hemodynamic effects, and anti-inflammatory action.
BP Reduction: Natriuresis-driven volume depletion enhances hypertension control.
Metabolic Shift: Promotes ketogenesis & energy deficit, boosting myocardial efficiency.
Renal Protection:
Preserves eGFR, reduces albuminuria via tubuloglomerular feedback and antifibrotic effects.
Metabolic/Liver:
Improves lipid profiles (↓LDL/triglycerides, ↑HDL) via ANGPTL4 inhibition.
Reduces hepatic steatosis/fibrosis and transaminases (ALT/AST/GGT).
Emerging Effects:
Neuroprotection: May lower dementia risk by mitigating neuroinflammation/oxidative stress.
Gut: Modulates NF-κB/IL-6 to reduce inflammation.
Antitumor: Alters tumor metabolism (Warburg effect reversal) and enhances PD-L1 degradation.
Caveat: Potential bone resorption (↑PTH/FGF-23, ↓calcium absorption).

06/08/2025

Diagnosis and Management of Hypertension in Adults: A Summary of BMJ NICE Guidelines

05/08/2025

Thrilled to unveil this stunning infographic visual overview of Cardiorenal Syndrome! 📊 Dive into its classification (Types 1-5 based on primary organ and dysfunction acuity), uncover the etiology (e.g., reduced renal perfusion, elevated venous pressure) 💧, and explore the dynamic bidirectional cardiac-renal interactions fueled by hemodynamic and neurohormonal alterations. ✨ by Abdallah Othman Cardiobeat Bybeat . share with colleagues, and like to support this effort! 🤗😍
📚 Sources: NHLBI, AHA, JACC, NIH.

04/08/2025

Varicose Veins Overview

03/08/2025

Secondary Tricuspid Regurgitation Progression in HFpEF/HFmrEF/HFrEF
Explore the phases of secondary tricuspid regurgitation (TR) linked to heart failure with preserved, mid-range, and reduced ejection fraction (HFpEF/HFmrEF/HFrEF):
Phase I: Increased LVEDP, mild sPAP elevation, mild RV/RA and TV annular dilatation.
Phase II: Progressive RV/RA dilatation, rising sPAP, TV annular dilatation, mild leaflet tethering.
Phase III: Excessive RV/RA dilatation, sustained sPAP, severe TV annular dilatation, excessive leaflet tethering, reduced forward SV.
Visualize the escalating impact on cardiac structure and function.

03/08/2025

Pulmonary Embolism (PE) – quick 🩻✨
🔹 Source: DVT (Virchow’s triad).
🔹 STOP CLOT Mnemonic:
Swelling | Tenderness | Out of breath
Pass out | Chest pain | Leg discoloration.Overdrive (HR up) | Time to act!
🔹 Massive PE? Syncope, hypoxia, RV strain on echo.
💡 Key Test:
ABG: Hypoxemia + Respiratory Alkalosis
CXR: Hampton hump / Westermark sign.
⚠️ TX: Anticoagulate NOW! (Thrombolytics if massive).

02/08/2025

02/08/2025